Janupally Renuka

Birla Institute of Technology and Science - Hyderabad Campus — India

Biochemistry, Genetics and Molecular Biology · Life Sciences

18h-index735citations28works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer therapeutics and mechanisms(22), Tuberculosis Research and Epidemiology(16), Synthesis and biological activity(8), Antibiotic Resistance in Bacteria(5), Pneumocystis jirovecii pneumonia detection and treatment(5)

Publications28 total

Layer-by-Layer Thin Films for Co-Delivery of TGF-β siRNA and Epidermal Growth Factor to Improve Excisional Wound Healing
AAPS PharmSciTech·2016· 37 cited
Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors
European Journal of Medicinal Chemistry·2016· 32 citedOpen Access
Structure‐Guided Discovery of Antitubercular Agents That Target the Gyrase ATPase Domain
ChemMedChem·2016· 10 cited
Polymer–gold nanoparticle composite films for topical application: Evaluation of physical properties and antibacterial activity
Polymer Composites·2015· 27 cited
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors
Bioorganic & Medicinal Chemistry·2015· 11 citedOpen Access
4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation
European Journal of Medicinal Chemistry·2015· 53 citedOpen Access
Structure-based virtual screening as a tool for the identification of novel inhibitors against Mycobacterium tuberculosis 3-dehydroquinate dehydratase
Journal of Molecular Graphics and Modelling·2015· 17 cited
Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors
International Journal of Mycobacteriology·2015· 29 citedOpen Access
Identification of potential Mycobacterium tuberculosis topoisomerase I inhibitors: A study against active, dormant and resistant tuberculosis
European Journal of Pharmaceutical Sciences·2015· 16 cited
Design and synthesis of novel quinoline–aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors
Bioorganic & Medicinal Chemistry·2015· 56 citedOpen Access
Corrigendum to “Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus” [Bioorg. Med. Chem. 22 (2014) 5970–5987]
Bioorganic & Medicinal Chemistry·2015· 2 cited
Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain
Bioorganic & Medicinal Chemistry·2015· 22 citedOpen Access
Design and Biological Evaluation of Furan/Pyrrole/Thiophene‐2‐carboxamide Derivatives as Efficient<scp>DNA</scp>GyraseB Inhibitors of<i>Staphylococcus aureus</i>
Chemical Biology & Drug Design·2015· 21 citedOpen Access
Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling
Organic & Biomolecular Chemistry·2014· 27 cited
Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: Hit to lead optimization of a novel class of thiazole inhibitors
Bioorganic & Medicinal Chemistry·2014· 24 cited
An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition
Bioorganic & Medicinal Chemistry·2014· 43 citedOpen Access
Mycobacterial DNA GyrB Inhibitors: Ligand Based Pharmacophore Modelling and In Vitro Enzyme Inhibition Studies
Current Topics in Medicinal Chemistry·2014· 4 cited
Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus
Bioorganic & Medicinal Chemistry·2014· 23 citedOpen Access
Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis
European Journal of Medicinal Chemistry·2014· 28 citedOpen Access
Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA
Bioorganic & Medicinal Chemistry·2014· 12 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Dharmarajan Sriram(26), Perumal Yogeeswari(24), Variam Ullas Jeankumar(16), Jonnalagadda Padma Sridevi(15), Shalini Saxena(11), Pushkar Kulkarni(10), Priyanka Suryadevara(8), Vijay Soni(6), Parthiban Brindha Devi(5), R. Reshma(4), Karyakulam Andrews Bobesh(4), Brahmam Medapi(3), Raghavender Medishetti(3), Venkat Koushik Pulla(3), Ganesh S. Pedgaonkar(3), K. Indrasena Reddy(2), Srihari Konduri(2), Shravan Morla(2), Kondra Sudhakar Babu(2), Suresh Narva(2)